Evidence & Transparency
How EvidentMeds sources, rates, and contextualises information - and what it doesn't do.
What EvidentMeds Is (and Isn't)
EvidentMeds is an educational reference built from publicly available clinical data - FDA prescribing information, peer-reviewed literature, ClinicalTrials.gov records, and government transparency databases.
It is not a substitute for medical advice, a diagnostic tool, or a treatment recommendation system. It does not know your medical history, current medications, lab values, or individual risk factors.
Every medication page is designed to help you ask better questions during a clinical appointment - not to make decisions independently of your prescribing physician.
Do not stop or change any medication based solely on information found here. Always consult your prescribing physician. For emergencies, call 911 or go to the nearest emergency room.
The Polypharmacy Problem
Polypharmacy - the concurrent use of five or more prescription medications - is associated with increased adverse drug events, hospitalizations, cognitive decline, and falls. Among U.S. veterans aged 65+, the average is 10+ concurrent medications.
The Prescribing Cascade
Side effects from one medication are misattributed to a new condition, leading to another prescription - and the cycle repeats.
Medication A
Causes nausea, insomnia
Medication B
Added for insomnia, causes dizziness
Medication C
Added for dizziness, causes fatigue
Medication D
Added for fatigue, causes weight gain
Each new prescription increases the likelihood of harmful interactions and compounding side effects.
Veteran Suicide & Psychotropic Polypharmacy
According to the VA's 2012 Suicide Data Report, approximately 22 veterans died by suicide each day in the United States. Updated VA data from the 2023 National Veteran Suicide Prevention Annual Report estimates this figure at roughly 17.5 per day. While the causes of veteran suicide are complex and multifactorial, peer-reviewed research has identified associations between concurrent psychotropic prescriptions and elevated suicide risk in veteran populations.
Studies suggest that veterans prescribed three or more psychotropic medications concurrently, combinations of antidepressants, benzodiazepines, opioids, and antipsychotics, may face increased risk of suicidal ideation and adverse psychiatric outcomes. The VA's own internal reviews have flagged the overuse of sedative and psychotropic combinations as a contributing factor warranting closer clinical oversight.
This is not to suggest that any single medication causes suicide - the research describes correlations and contributing factors within complex clinical pictures. But it underscores why transparent medication data, drug interaction visibility, and evidence-based deprescribing guidance matter. These are problems that better information can help address.
Veterans Crisis Line
If you or someone you know is in crisis, call 988 (press 1 for veterans), text 838255, or chat at VeteransCrisisLine.net.
Why EvidentMeds Was Built For This
EvidentMeds is a veteran-owned platform built in part because of this problem. Every medication profile in our directory is designed to surface the data that matters most in polypharmacy decisions:
Commonly Over-Prescribed Drug Classes in Veteran Populations
Sources: VA Suicide Data Report (2012), National Veteran Suicide Prevention Annual Report (2023), VA Polypharmacy Clinical Guidance (2019), Maher et al. "Clinical consequences of polypharmacy in elderly" Expert Opinion on Drug Safety (2014), Mojtabai & Olfson "National trends in psychotropic medication polypharmacy" Archives of General Psychiatry (2010).
How We Use Language
EvidentMeds applies a deliberate language standard to avoid overstating certainty. You will see:
Conditional language throughout
"suggests," "may," "appears," "is associated with" - not "proves," "always," "guaranteed," or "cures."
Source attribution on every claim
Funding sources, study names, and regulatory documents are named and linked so you can verify independently.
Context without accusation
Industry funding and payment disclosures are presented as context, not evidence of wrongdoing. Conflict disclosure is legally required - not inherently disqualifying.
No absolute claims about safety or efficacy
Efficacy data reflects trial averages, not individual outcomes. "Works for X% of patients in trial Y" is very different from "will work for you."
Risk of Bias Ratings (Cochrane RoB-2)
Each clinical trial listed on medication pages carries a risk-of-bias badge. These are editorial assessments using the framework developed by the Cochrane Collaboration - the global standard for evaluating randomised controlled trials. They are not certified Cochrane reviews.
The five RoB-2 domains assessed
- 1Randomization process: Was allocation concealed? Was the sequence truly random?
- 2Deviations from intended interventions: Did participants receive what was assigned?
- 3Missing outcome data: Is data loss balanced and explained?
- 4Measurement of the outcome: Was the outcome assessed in an unbiased way?
- 5Selection of the reported result: Was the outcome pre-specified, or chosen after seeing the data?
Badge meanings
No major methodological concerns identified across the five domains. Typically independent or government-funded RCTs with pre-registered outcomes.
One or more domains raise questions, most commonly industry sponsorship, open-label design, or incomplete outcome reporting. Results may still be valid but warrant caution.
Significant design or reporting concerns, often observational studies, retrospective analyses, or trials with substantial missing data. Results should be interpreted cautiously.
Not a randomised trial, applies to regulatory documents, legal settlements, meta-analyses, or systematic reviews (which are assessed using ROBIS, not RoB-2).
CMS Open Payments
The Physician Payments Sunshine Act (enacted 2010, data from 2013) requires pharmaceutical and medical device companies to publicly report all payments made to U.S. physicians and teaching hospitals. This database is administered by the Centers for Medicare & Medicaid Services (CMS) and is called Open Payments.
Reported payments include: consulting fees, speaking honoraria, meals and travel, research funding, ownership or investment interests, and royalties.
What Open Payments tells us - and what it doesn't
It tells us
- Which companies paid a physician
- How much was paid and for what category
- Whether a prescriber has a financial relationship with a manufacturer
- The years those payments occurred
It does not tell us
- Whether a payment influenced a specific prescribing decision
- Whether a physician acted inappropriately
- Whether the medication itself is good or bad
- Whether you should change your treatment
"Payments alone do not prove bias or misconduct. Disclosure is legally required, it is context, not condemnation."
Pharmaceutical Lobbying & Political Spending
While CMS Open Payments tracks what pharmaceutical companies pay physicians, a parallel system of public disclosure tracks what the industry spends to influence legislation and regulation. This data is reported through federal lobbying disclosures and Federal Election Commission (FEC) filings.
According to data compiled by OpenSecrets (a nonpartisan research organization tracking money in politics), the pharmaceutical and health products sector has consistently ranked among the top lobbying spenders in Washington. In recent years, the industry has reported spending over $350 million annually on federal lobbying, more than any other single industry sector.
This spending is legal, disclosed, and publicly searchable. EvidentMeds presents it as context, the same way we present physician payment data, because the policy environment in which medications are approved, priced, and prescribed does not exist in a vacuum.
What lobbying disclosure tells us, and what it doesn't
It tells us
- How much each company or trade group spends on lobbying annually
- Which legislative issues they are lobbying on (drug pricing, FDA regulation, patent law)
- How much PAC money flows to congressional campaigns and committees
- Which former government officials now lobby for the industry
It does not tell us
- Whether lobbying changed a specific legislator's vote
- Whether any policy outcome was directly "purchased"
- Whether the industry's policy positions are right or wrong
- Whether your medication's price was affected by a specific lobbying effort
The Revolving Door
Public records show a well-documented pattern of personnel movement between federal regulatory agencies (FDA, CMS, HHS) and the pharmaceutical industry. Former regulators frequently move into lobbying, consulting, or executive roles at the companies they previously oversaw - and industry executives sometimes move into government positions that shape drug policy.
This "revolving door" is legal and publicly disclosed. It does not prove that any individual acted improperly. However, researchers and government watchdog organizations have noted that these career transitions may create institutional relationships that influence how regulations are written, how quickly drugs are approved, and how aggressively pricing is overseen.
Why This Matters for Medication Policy
Lobbying and political spending may influence several areas that directly affect the medications patients are prescribed:
"Lobbying is legal activity protected by the First Amendment. Disclosure provides context for understanding the policy environment in which prescribing decisions are shaped, not evidence that any specific policy outcome was improperly influenced."
Pharma lobbying data
OpenSecrets - pharmaceutical industry lobbying totals and trends
PAC & campaign contributions
OpenSecrets - pharma industry political contributions
Sources: OpenSecrets.org (Center for Responsive Politics), Federal Election Commission (FEC) public filings, Government Accountability Office reports on the FDA revolving door, Pew Charitable Trusts research on guideline committee conflicts of interest.
Medical Disclaimer
The content on EvidentMeds is compiled from publicly available sources including FDA prescribing information, ClinicalTrials.gov records, peer-reviewed journal articles, and government databases. It is provided for educational and informational purposes only.
In the United States: For medical emergencies, call 911. Poison Control Center: 1-800-222-1222. SAMHSA Substance Use Helpline: 1-800-662-4357. National Suicide Prevention Lifeline: 988.
Primary Sources We Use
FDA Drug Database (DailyMed)
Official FDA prescribing information and labeling
ClinicalTrials.gov
Registry of U.S. and international clinical studies
PubMed / MEDLINE (NIH)
Peer-reviewed biomedical and life science literature
Cochrane Library
Systematic reviews and meta-analyses
CMS Open Payments
Pharmaceutical industry payment disclosures
MedlinePlus (NIH)
Patient-facing drug and condition information
ICER Evidence Reports
Independent comparative effectiveness and pricing analysis
FDA Adverse Event Reporting
Post-market safety surveillance data
EvidentMeds · For educational purposes only · Not medical advice